NCT02920710 is a Phase 4 clinical trial of Repository Corticotropin Injection in Sarcoidosis, sponsored by The Cleveland Clinic.

Who is sponsoring NCT02920710?

NCT02920710 is sponsored by The Cleveland Clinic.

What drugs are being tested in NCT02920710?

Interventions in NCT02920710: Repository Corticotropin Injection.

What condition does NCT02920710 study?

NCT02920710 studies Sarcoidosis.

Is NCT02920710 still recruiting?

NCT02920710 is currently withdrawn. Last updated 20 November 2020.

Last reviewed 2020-11-20 · How we verify

NCT02920710

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ACTHAR Therapy for Central Nervous System Sarcoidosis

Withdrawn Phase 4 Last updated 20 November 2020

What this trial tests

Phase 4 trial testing Repository Corticotropin Injection in Sarcoidosis. Withdrawn.

Timeline

1 February 2019

Primary endpoint
2 November 2020

2 November 2020

Quick facts

Lead sponsor	The Cleveland Clinic
Phase	Phase 4
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	1 February 2019
Primary completion	2 November 2020
Estimated completion	2 November 2020
Sites	1 location across United States

Drugs / interventions tested

Repository Corticotropin Injection — full drug profile →

Conditions studied

Sarcoidosis — all drugs for Sarcoidosis →

Sponsor

The Cleveland Clinic

Who can join

Eligibility, any sex, with Sarcoidosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

There is a need for a more reliable, expeditious therapy that can be used as an alternative to glucocorticoids in severe Central Nervous System (CNS) sarcoidosis. This study aims to provide evidence for effectiveness of ACTHAR gel in CNS sarcoidosis, and provide information about its safety and tolerability

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Refractory Sarcoidosis: A Review.
El Jammal T, Jamilloux Y, Gerfaud-Valentin M, Valeyre D, et al · · 2020 · cited 45× · PMID 32368072 · DOI 10.2147/tcrm.s192922
Clinical and immunological study of Tofacitinib and Baricitinib in refractory Blau syndrome: case report and literature review.
Álvarez-Reguera C, Prieto-Peña D, Herrero-Morant A, Sánchez-Bilbao L, et al · · 2022 · cited 14× · PMID 35510170 · DOI 10.1177/1759720x221093211

Verify or expand the search:

Other recruiting trials for Sarcoidosis

Currently open trials in the same condition.

NCT07498842 — Corticosteroid Tapering in Sarcoidosis · NA · recruiting
NCT07073963 — Virtual Patient Groups for Sarcoidosis Associated Fatigue · NA · recruiting
NCT07384897 — Immune Cells Role in Lung Cancer and Their Use in Anticancer Immunotherapies and Inflammatory Lung Disease · NA · recruiting
NCT06636487 — Expand Pulmonary Rehabilitation to Other Chronic Respiratory Diseases Than COPD · NA · active not recruiting
NCT06576505 — Immunological Mechanisms in Sarcoidosis · recruiting

Other The Cleveland Clinic trials

Trials by the same sponsor.

NCT07218198 — Clinical Decision Support Tool for the Treatment of Uncontrolled Hypertension · NA · not yet recruiting
NCT07442747 — Neural Mechanisms of Aerobic Exercise Benefits in PD With DBS · NA · not yet recruiting
NCT07471464 — Centered Surgery - Preoperative Counseling and Patient Satisfaction · recruiting
NCT07073963 — Virtual Patient Groups for Sarcoidosis Associated Fatigue · NA · recruiting
NCT07363343 — Nifedipine and Enalapril vs Nifedipine and Labetalol for the Treatment of Postpartum Hypertension Study · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02920710 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Cleveland Clinic
Last refreshed: 20 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02920710.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing